Ionis Pharmaceuticals Bolsa (NASDAQ: IONS)

Últimas noticias sobre Ionis Pharmaceuticals (NASDAQ:IONS) Bolsa

Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals Inc

<p>Morgan Stanley  analyst Nigel Dally   maintains Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) with a Equal-Weight and raises the price target from $123 to $125.</p>


News

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Globe Life, Raises Price Target to $125

<p><a href="https://www.youtube.com/watch?v=aavRKJYuJkE" title="https://www.youtube.com/watch?v=aavRKJYuJkE">https://www.youtube.com/watch?v=aavRKJYuJkE</a></p>


Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says We Want To Run A Strong Labor Market, One Of The Benefits Is That Black-white Employment Gap Comes Down

<p>Benchmark  analyst Mike Hickey   maintains Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) with a Buy and raises the price target from $16 to $18.</p>


GAMB

Benchmark Maintains Buy on Gambling.com Gr, Raises Price Target to $18

<p>Morgan Stanley  analyst Vincent Andrews   maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Equal-Weight and lowers the price target from $90 to $74.</p>


Morgan Stanley Maintains Equal-Weight on Bunge Global, Lowers Price Target to $74

Fed Chair Powell Says Fed Pursuing Mandate Is Single Best Thing Fed Can Do To Narrow Gaps By Race; Still Have Quite A Bit Of Equity Data On Our Website

GM CEO: We Think We Can Mitigate 30% To 50% Of Tariffs Without Deploying Capital

WIIM

INTC

Intel shares are trading higher after reviewers praised its latest processor, the Core Ultra 9 275HX, as the "fastest chip yet".

<p><a href="http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/" title="http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/">http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/</a></p>


Meta Is In Talks To Acquire South Korean AI Chip Startup Furiosaai

Guidance

CORRECTION: FIS Expects Q1 2025 Revenue Of $2.485B - $2.510B Vs. $2.57B Estimate, Adjusted EPS Of $1.17-$1.22 Vs. $1.28 Estimate

<p>JMP Securities  analyst Mitch Germain   maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Market Outperform and lowers the price target from $35 to $32.</p>


SAFE

JMP Securities Maintains Market Outperform on Safehold, Lowers Price Target to $32

Fed Chair Powell Says Don't Believe Musk Or Team Has Tried To Access Fed Systems; Commit To Letting Committee Know If So

<p><em>Editor&#8217;s note: This story has been updated with additional details. </em></p>
<p>Federal Reserve Chair<strong> Jerome Powell</strong> reiterated on Tuesday that policymakers are in no "hurry" to adjust interest rates, citing lingering inflation pressures despite significant progress toward the<a href="https://www.benzinga.com/news/econ-s"> Fed's 2% inflation goal.</a></p>
<p>Speaking before the Senate Banking Committee in Washington, Powell described the economic landscape as one where "the economy is strong overall." with a labor market that has cooled from its overheated state but remains resilient.</p>
<p>Over the past four months, payroll job gains averaged 189,000 per month, while the unemployment rate held steady at 4% in January. Powell indicated that "the labor market is not a source of significant inflationary pressures."</p>
<p>On inflation, Powell highlighted a notable decline over the past two years but stressed that "inflation remains somewhat elevated."</p>
<p>The latest Personal Consumption Expenditures price index showed a 2.6% year-over-year increase as of December, with core PCE rising 2.8%, excluding volatile food and energy costs. </p>
<h3 class="wp-block-heading">Powell Stresses Caution In Interest Rate Policy</h3>
<p>Since September, the Federal Open Market Committee has lowered the policy rate by a full percentage point from its peak. </p>
<p>Powell described this shift as "appropriate in light of the progress on inflation and the cooling in the labor market."</p>
<p>Despite these moves, Powell reiterated that "we do not need to be in a hurry to adjust our policy stance." </p>
<p>He stated that reducing interest rates &#8220;too fast or too much&#8221; could derail progress on inflation, while moving too slowly or too little "could unduly weaken economic activity and employment."</p>
<p>Going forward, the Fed will continue to remain data dependent, before making further policy adjustments.</p>
<h3 class="wp-block-heading">Powell Pushes Back Recession Concerns, Refrains From Tariff Judgement</h3>
<p>During the Q&amp;A session, Powell pushed back against recession risks and reiterated the broader strength of the economy. </p>
<p>Sen.<strong> John Kennedy</strong> (R-LA) questioned the Fed's influence over long-term bond yields, to which Powell responded, "We have some influence, but mostly not." </p>
<p>The Fed Chair indicated that long-term rates are driven by future short-term rate expectations, inflation risks, and the budget deficit—factors beyond the Fed's direct control. </p>
<p>When asked if a president could remove a Federal Reserve Board member, Powell said, "It's not allowed under the law."</p>
<p>Sen. <strong>Bill Hagerty</strong> (R-TN) asked Powell if the neutral rate — the point where interest rates neither boost nor slow the economy — has risen.</p>
<p>&#8220;The neutral rate will have risen meaningfully," Powell said.</p>
<p>The chairman highlighted that concerns over labor market weakness and inflation have faded. Powell said that many of his colleagues also believe the neutral rate has moved higher, a shift from its historically low pre-pandemic levels.</p>
<p>On trade policy, Sen. <strong>Jack Reed</strong> (D-RI) referenced Powell's 2018 statement that "countries that have remained open to trade, that have not erected barriers, including tariffs, have grown faster and achieved higher incomes." </p>
<p>Powell stood by that view but refrained from commenting on specific trade policies, including <strong>President Donald Trump</strong>'s tariffs on China, Canada, and Mexico. </p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/43627524/economists-betting-markets-predict-benign-january-inflation-what-could-go-wrong-this-time">Economists, Betting Markets Predict Benign January Inflation: What Could Go Wrong This Time?</a></strong></li>
</ul>


Econ #s

Fed's Powell Reiterates No 'Hurry' To Cut Interest Rates As Inflation Remains 'Somewhat Elevated' (UPDATED)

Fed Chair Powell Says Seeing Insurance Pulling Out Of Parts Of Country, Would Have Significant Economic Consequences But Not Necessarily A Financial Stability Concern; Powell: Concern On Labor Market Has Diminished Considerably Since Mid-last Year

<p>Morgan Stanley  analyst Vincent Andrews   maintains Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) with a Equal-Weight and lowers the price target from $52 to $47.</p>


Morgan Stanley Maintains Equal-Weight on Archer-Daniels Midland, Lowers Price Target to $47

<p>Morgan Stanley  analyst Michael Cyprys   maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Equal-Weight and raises the price target from $169 to $170.</p>


Morgan Stanley Maintains Equal-Weight on Apollo Global Management, Raises Price Target to $170

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Intuitive Machines</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LUNR, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 18 options trades for <strong>Intuitive Machines</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 50%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $31,620, and 17, calls, for a total amount of $864,107.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $25.0 for Intuitive Machines over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Intuitive Machines options trades today is 2439.8 with a total volume of 18,107.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Machines's big money trades within a strike price range of $10.0 to $25.0 over the last 30 days.</p>
<h3>Intuitive Machines Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739291431_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.6</td>
<td>$10.85</td>
<td>$11.6</td>
<td>$10.00</td>
<td>$140.3K</td>
<td>7.9K</td>
<td>121</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.55</td>
<td>$11.55</td>
<td>$11.6</td>
<td>$10.00</td>
<td>$116.0K</td>
<td>7.9K</td>
<td>300</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$0.99</td>
<td>$0.96</td>
<td>$0.98</td>
<td>$20.00</td>
<td>$78.6K</td>
<td>2.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.2</td>
<td>$1.13</td>
<td>$1.13</td>
<td>$21.00</td>
<td>$54.5K</td>
<td>856</td>
<td>517</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$0.7</td>
<td>$0.56</td>
<td>$0.7</td>
<td>$20.00</td>
<td>$43.3K</td>
<td>2.2K</td>
<td>2.6K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Machines</h3>
<p>Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure.</p>
<p>In light of the recent options history for Intuitive Machines, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Intuitive Machines Standing Right Now?</h3>
<ul>
<li>With a volume of 4,109,237, the price of LUNR is down -4.07% at $19.12. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>Expert Opinions on Intuitive Machines</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $16.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities has revised its rating downward to Underperform, adjusting the price target to $16. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Intuitive Machines options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

LUNR

Decoding Intuitive Machines's Options Activity: What's the Big Picture?

<p>JMP Securities  analyst Brian McKenna   reiterates Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Market Outperform and maintains $32 price target.</p>


Reiteration

JMP Securities Reiterates Market Outperform on Blue Owl Cap, Maintains $32 Price Target

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Nike</strong>.</p>
<p>Looking at options history for Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) we detected 26 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 38% with bearish.</p>
<p>From the overall spotted trades, 14 are puts, for a total amount of $2,030,410 and 12, calls, for a total amount of $571,236.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $120.0 for Nike, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Nike's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Nike's whale trades within a strike price range from $50.0 to $120.0 in the last 30 days. </p>
<h3>Nike Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739291426_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$9.35</td>
<td>$8.35</td>
<td>$9.02</td>
<td>$67.50</td>
<td>$1.3M</td>
<td>2.3K</td>
<td>1.5K</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$15.5</td>
<td>$14.9</td>
<td>$15.2</td>
<td>$70.00</td>
<td>$91.2K</td>
<td>1.0K</td>
<td>81</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$75.00</td>
<td>$74.4K</td>
<td>5.7K</td>
<td>805</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$75.00</td>
<td>$74.4K</td>
<td>5.7K</td>
<td>925</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$75.00</td>
<td>$71.5K</td>
<td>4.2K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Nike</h3>
<p>Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.</p>
<h3>Nike's Current Market Status</h3>
<ul>
<li>With a volume of 3,534,698, the price of NKE is down -0.62% at $70.5. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>Professional Analyst Ratings for Nike</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $82.75.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Neutral, setting a price target of $72.<br />
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $84.<br />
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Market Perform rating for Nike, targeting a price of $80.<br />
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Nike, maintaining a target price of $95. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Nike, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Nike Unusual Options Activity

<p>Roth MKM  analyst Suji Desilva   maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $100 to $60.</p>


Roth MKM Maintains Buy on ON Semiconductor, Lowers Price Target to $60

<p>Financial giants have made a conspicuous bullish move on Coca-Cola. Our analysis of options history for Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) revealed 21 unusual trades.</p>
<p>Delving into the details, we found 57% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $181,525, and 17 were calls, valued at $5,454,079.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $70.0 for Coca-Cola during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Coca-Cola's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Coca-Cola's whale activity within a strike price range from $55.0 to $70.0 in the last 30 days. </p>
<h3>Coca-Cola Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739291421_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>KO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.85</td>
<td>$9.75</td>
<td>$9.85</td>
<td>$62.50</td>
<td>$3.6M</td>
<td>15.2K</td>
<td>3.7K</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.8</td>
<td>$9.6</td>
<td>$9.8</td>
<td>$62.50</td>
<td>$911.4K</td>
<td>15.2K</td>
<td>3.7K</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.8</td>
<td>$4.8</td>
<td>$5.33</td>
<td>$62.50</td>
<td>$220.6K</td>
<td>4.1K</td>
<td>403</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.1</td>
<td>$2.83</td>
<td>$3.0</td>
<td>$64.00</td>
<td>$82.2K</td>
<td>5.1K</td>
<td>615</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.05</td>
<td>$2.84</td>
<td>$2.92</td>
<td>$64.00</td>
<td>$81.7K</td>
<td>5.1K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Coca-Cola</h3>
<p>Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around two thirds of its total revenue overseas, with a significant portion from emerging economies in Latin America and Asia-Pacific.</p>
<p>After a thorough review of the options trading surrounding Coca-Cola, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Coca-Cola Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 13,800,013, with KO's price up by 3.18%, positioned at $66.61.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for Coca-Cola</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $71.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Coca-Cola, which currently sits at a price target of $72.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Coca-Cola, which currently sits at a price target of $73.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Coca-Cola, which currently sits at a price target of $70.<br />
&#x2A; An analyst from Jefferies upgraded its action to Buy with a price target of $75.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Coca-Cola, targeting a price of $66. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Coca-Cola, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Spotlight on Coca-Cola: Analyzing the Surge in Options Activity

Ionis Pharmaceuticals (IONS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Ionis Pharmaceuticals: Strategic Path to Cash Flow Positivity and Strong Pipeline Drive Buy Rating

David Lebowitz, an analyst from Citi, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The associated price target rema...

Ionis Pharmaceuticals: Promising Pipeline and Strategic Shifts Drive Buy Rating

RBC Capital analyst Luca Issi reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $70.00. The...

RBC Capital Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...

Ionis Pharmaceuticals: Strong Pipeline and Market Potential Drive 'Buy' Rating

Biogen wins U.S. EU review for higher dose version of SMA drug marketed with Ionis

Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential

Ionis (IONS) partner Novartis (NVS) shared in their year-end earnings report that Phase 3 pelacarsen data is now expected in the first half of 2026...

Ionis 'remains confident in pelacarsen' after Novartis update on Phase 3 timing

Novartis delays Phase 3 readout for Ionis heart drug

Tweedy, Browne Fund Q4 2024 Commentary

Tweedy, Browne Fund Q2 2024 Commentary

AALBF

ABLGF

ADKCF

BACRP

BIIB

COCSF

COPY

CVSGF

DBSDF

DBSDY

DGEAF

DHLGY

DPSTF

EPDU

FMCQF

FUJHF

FUJHY

GOOG

GOOGL

HAIIF

HEINY

HINKF

IONS

KOYJF

KURRF

KURRY

MBGCF

NGKSF

NGKSY

NHNKF

NHNKY

NIFCF

NIFCY

NSRGF

NSRGY

NVSEF

NVST

POAHF

POAHY

RBSFY

RHHBF

RHHBY

RHHVF

RNMBF

RNMBY

RPRX

RUBSF

SAFRF

SAFRY

SOHVF

SOHVY

SSNLF

TCEHY

TCTZF

TDAAF

TLPFF

TLPFY

UBSFF

UBSFY

UNPSF

UOVEF

UOVEY

UPCHY

VRTX

WFCNP

Earnings

Press Releases

Ionis reports third quarter 2024 financial results

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis to present at upcoming investor conferences

Health Care

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

Comments

Ionis Pharmaceuticals

Noticias

Últimas noticias sobre Ionis Pharmaceuticals (NASDAQ:IONS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL